Literature DB >> 24619287

Assessment of early renal damage in diabetic rhesus monkeys.

Dan Wang1, Jingping Liu, Sirong He, Chengshi Wang, Younan Chen, Lichaun Yang, Fang Liu, Yan Ren, Haoming Tian, Guang Yang, Guangneng Liao, Lan Li, Meimei Shi, Yujia Yuan, Jiuming Zhao, Jingqiu Cheng, Yanrong Lu.   

Abstract

The objectives of the study were to improve the model system of diabetic nephropathy in nonhuman primates and assess the early renal damage. Diabetes was induced in monkeys by streptozotocin, and the animals were administered exogenous insulin to control blood glucose (BG). Animals were divided into four groups, including the normal group (N = 3), group A (streptozotocin diabetic model with control of BG < 10 mmol/L, N = 3), group B (streptozotocin diabetic model with control of BG between 15 and 20 mmol/L, N = 4), and group C (streptozotocin diabetic model with control of BG between 15 and 20 mmol/L and high-sodium and high-fat diet, N = 4). The following parameters were evaluated: (1) blood biochemistry and routine urinalysis, (2) color Doppler ultrasound, (3) angiography, (4) renal biopsy, and (5) renal fibrosis-related gene expression levels. Animals in group C developed progressive histologic changes with typical diabetic nephropathy resembling diabetic nephropathy in human patients and exhibited accelerated development of diabetic nephropathy compared with other nonhuman primate models. Significant changes in the expression of the Smad2/3 gene and eNOS in renal tissue were also observed in the early stage of diabetic nephropathy. In conclusion, our model is an excellent model of diabetic nephropathy for understanding the pathogenesis of diabetic nephropathy.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24619287     DOI: 10.1007/s12020-014-0211-4

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  33 in total

Review 1.  Treatment targets in renal fibrosis.

Authors:  Peter Boor; Katarína Sebeková; Tammo Ostendorf; Jürgen Floege
Journal:  Nephrol Dial Transplant       Date:  2007-09-21       Impact factor: 5.992

2.  Expression of transforming growth factor-beta and type IV collagen in early streptozotocin-induced diabetes.

Authors:  I S Park; H Kiyomoto; S L Abboud; H E Abboud
Journal:  Diabetes       Date:  1997-03       Impact factor: 9.461

3.  Hypertension prevalence, awareness, treatment, and control in an adult type 1 diabetes population and a comparable general population.

Authors:  David M Maahs; Gregory L Kinney; Paul Wadwa; Janet K Snell-Bergeon; Dana Dabelea; John Hokanson; James Ehrlich; Satish Garg; Robert H Eckel; Marian J Rewers
Journal:  Diabetes Care       Date:  2005-02       Impact factor: 19.112

4.  Treatment and risk factor analysis of hypoglycemia in diabetic rhesus monkeys.

Authors:  Sirong He; Younan Chen; Lingling Wei; Xi Jin; Li Zeng; Yan Ren; Jie Zhang; Li Wang; Hongxia Li; Yanrong Lu; Jingqiu Cheng
Journal:  Exp Biol Med (Maywood)       Date:  2011-02

5.  Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus.

Authors: 
Journal:  JAMA       Date:  2002-05-15       Impact factor: 56.272

6.  Pathologic classification of diabetic nephropathy.

Authors:  Thijs W Cohen Tervaert; Antien L Mooyaart; Kerstin Amann; Arthur H Cohen; H Terence Cook; Cinthia B Drachenberg; Franco Ferrario; Agnes B Fogo; Mark Haas; Emile de Heer; Kensuke Joh; Laure H Noël; Jai Radhakrishnan; Surya V Seshan; Ingeborg M Bajema; Jan A Bruijn
Journal:  J Am Soc Nephrol       Date:  2010-02-18       Impact factor: 10.121

7.  Urinary and renal interstitial concentrations of TNF-alpha increase prior to the rise in albuminuria in diabetic rats.

Authors:  Kambiz Kalantarinia; Alaa S Awad; Helmy M Siragy
Journal:  Kidney Int       Date:  2003-10       Impact factor: 10.612

8.  Renal connective tissue growth factor correlates with glomerular basement membrane thickness and prospective albuminuria in a non-human primate model of diabetes: possible predictive marker for incipient diabetic nephropathy.

Authors:  Sally E Thomson; Susan V McLennan; Paul D Kirwan; Scott J Heffernan; Annemarie Hennessy; Dennis K Yue; Stephen M Twigg
Journal:  J Diabetes Complications       Date:  2008-04-16       Impact factor: 2.852

9.  Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study.

Authors:  Y Ohkubo; H Kishikawa; E Araki; T Miyata; S Isami; S Motoyoshi; Y Kojima; N Furuyoshi; M Shichiri
Journal:  Diabetes Res Clin Pract       Date:  1995-05       Impact factor: 5.602

10.  Effect of salt on hypertension and oxidative stress in a rat model of diet-induced obesity.

Authors:  Anca D Dobrian; Suzanne D Schriver; Terrie Lynch; Russell L Prewitt
Journal:  Am J Physiol Renal Physiol       Date:  2003-06-10
View more
  4 in total

Review 1.  Age-Associated Pathology in Rhesus Macaques (Macaca mulatta).

Authors:  H A Simmons
Journal:  Vet Pathol       Date:  2016-02-10       Impact factor: 2.221

2.  Quantitative assessment of renal damage in rhesus monkeys with diabetic nephropathy using contrast-enhanced ultrasound.

Authors:  Wenwu Ling; Yulan Peng; Hong Wang; Xingxing An; Yanrong Lu
Journal:  Ann Transl Med       Date:  2022-03

3.  Nephroprotective Effects of Tetramethylpyrazine Nitrone TBN in Diabetic Kidney Disease.

Authors:  Mei Jing; Yun Cen; Fangfang Gao; Ting Wang; Jinxin Jiang; Qianqian Jian; Liangmiao Wu; Baojian Guo; Fangcheng Luo; Gaoxiao Zhang; Ying Wang; Lipeng Xu; Zaijun Zhang; Yewei Sun; Yuqiang Wang
Journal:  Front Pharmacol       Date:  2021-06-24       Impact factor: 5.810

4.  Intervention for early diabetic nephropathy by mesenchymal stem cells in a preclinical nonhuman primate model.

Authors:  Xingxing An; Guangneng Liao; Younan Chen; Ai Luo; Jingping Liu; Yujia Yuan; Lan Li; Lichuan Yang; Hong Wang; Fang Liu; Guang Yang; Shounan Yi; Yuanmin Li; Jingqiu Cheng; Yanrong Lu
Journal:  Stem Cell Res Ther       Date:  2019-12-02       Impact factor: 6.832

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.